学科与关键词
关键词
t(821) AMLCD19measurable residual diseasepost-remission treatmentallo-SCTchematherapy
- Dynamic Assessment of Measurable Residual Disease in Favorable-Risk Acute Myeloid Leukemia in First Remission, Treatment, and OutcomesYu, Sijian, Sr.; Liu, Qifa63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA, 2021-12-11 To 2021-12-14.
- Minimal Residual Disease after the 2nd Induction Course Predicted Outcomes in Chinese Children with Acute Myeloid Leukaemia Treated According to the C-Huanan-AML 15 ProtocolZhi, Zheng Yong; Feng, Xiaoqin; Li, Chunfu; Zheng, Mincui; Mai, Huirong; Yang, Lihua; He, Yingyi; He, Xiangling; Xu, Honggui; Wen, Hong; Li, Jian; Hu, Jianda64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
- Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim AxisYu, Guopan; Yin, Zhao; Yao, Zurong; Nie, Xiaqi; Jin, Hua; Zhang, Yu; Xu, Dan; Jiang, Xuejie; Ping, Baohong65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
